



AF 1614 #

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No.: 09/717,746
Filing Date: 11/21/2000
Applicants: Herbert M. Dean et al.
Title: CARDIOPROTECTIVE DOSAGE UNITS
Art Unit: 1614
Examiner: Donna A. Jagoe

RECEIVED
NOV 29 2002
TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Enclosed for filing in the above-referenced patent application please find an Amendment and Request for Reconsideration Pursuant to 37 CFR §1.116, a Petition for Extension of Time, a check in the amount of \$55.00 for the extension, and a return postcard.

Respectfully submitted,


Robert R. Deleault, Esq.
Reg. No. 39,165
Attorney for Applicants
41 Brook Street
Manchester, NH 03104
Tel. (603) 668-1971

Dated: 11/20/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on:

November 20, 2002
Robert R. Deleault
Robert R. Deleault



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

NOV 29 2002

RECEIVED

#8/B
(NE)
JRP
12/4/02

U.S. Serial No.: 09/717,746
Filing Date: 11/21/2000
Applicants: Herbert M. Dean et al.
Title: CARDIOPROTECTIVE DOSAGE UNITS
Art Unit: 1614
Examiner: Donna A. Jagoe

Paper No. _____

AMENDMENT AND REQUEST FOR RECONSIDERATION
PURSUANT TO 37 CFR § 1.116

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants respectfully request that the following amendments to the Application be entered:

IN THE CLAIMS:

Please substitute the following claims for the like numbered claims in the application:

1. A medicament dosage unit consisting essentially of a beta-adrenergic blocker and a platelet inhibitor together in a single dosage unit quantity sufficient to provide a cardiovascular protective dosage.
9. A method of treating cardiovascular disease said method comprising:
formulating a single dosage unit consisting essentially of a beta-adrenergic blocking agent and a platelet inhibitor in a single dosage unit quantity sufficient to provide a cardiovascular protective dosage; and
administering said single dosage unit to a patient.

OK to
enter
12/13/02
JRP